http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Chi-Un Pae,Changsu Han,Won-Myong Bahk,Soo-Jung Lee,Ashwin A. Patkar,Prakash S. Masand 대한정신약물학회 2021 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.19 No.2
Objective: In a number of controlled clinical trials and naturalistic studies, aripiprazole once monthly (AOM) has been found to be effective and safe as acute and maintenance treatment options for schizophrenia. However, such clinical data have been presented in selected patient population (i.e., antipsychotic monotherapy, etc.), in particular, clinical information on switching to AOM from antipsychotic polypharmacy and/or other long acting injectable antipsychotics (LAIs) has been scarce till today. Methods: The study period was from the first switching day to AOM up to 12 months in patients with antipsychotic polypharmacy (APpoly)/LAIs (baseline, month 3, month 6, and month 12). Available demographics and clinical in-formation were retrieved from electronic medical records (EMRs). Available scores of Global Assessment of Functioning (GAF), Clinical Global Impression-Clinical Benefit (CGI-CB), CGI-severity, Visual Analog Scale on Satisfaction-Patient/Health Professional (VAS-P/HP), and the Positive and Negative Syndrome Scale-Insigh (PANSS-I) scores were also taken from EMR. Proportional change of functional impairment before and after AOM was also captured. Results: Data of 18 patients were available. Most commonly used combined APs before AOM were aripiprazole, blo-nanserin, quetiapine, and risperidone. At least 2 APs (n = 2.4) were combined before AOM. Scores of GAF (10.7% increase), CGI-CB (46.2% decrease), VAS-P (47.8% increase), VAS-HP (40.8% increase), and PANSS-I (27.9% increase) (all p = 0.001) were significantly improved from baseline to month 12, respectively. Approximately 59% of patients improved individual functioning with different level (i.e., employment, back to school, etc.) after AOM treatment at month 12. Conclusion: The present study have clearly shown the clinical benefit and utility of switching to AOM for treatment of patients with APpoly/LAIs in routine practice. Subsequent, adequately-powered, well-controlled clinical trials may be necessary to confirm our findings in near future.
HMM(Hidden Markov Model) 기반 견고한 실시간 립리딩을 위한 효율적인 VLSI 구조 설계와 FPGA 구현을 이용한 검증
이지근(Chi-Geun Lee),소인미(In-Mi So),김영운(Young-Un Kim),김주리(Ju-Ri Kim),강선경(Sun-Kyoung Kang),정성태(Sung-Tae Jung) 한국멀티미디어학회 2006 한국멀티미디어학회 학술발표논문집 Vol.2006 No.1
립리딩은 잡음이 있는 환경에서 음성 인식 시스템의 성능 향상을 위한 한 방법으로 제안되었다. 기존의 논문들이 소프트웨어 립리딩 방법을 제안하는 것에 반하여, 본 논문에서는 실시간 립리딩을 위한 하드웨어 설계를 제안한다. 실시간 처리와 구현의 용이성을 위하여 본 논문에서는 립리딩 시스템을 이미지 획득 모듈, 특징 벡터 추출 모듈, 인식 모듈의 세 모듈로 분할하였다. 이미지 획득 모듈에서는 CMOS 이미지 센서를 사용하여 입력 영상을 획득하게 하였고, 특징 벡터 추출 모듈에서는 병렬 블록매칭 알고리즘을 이용하여 입력영상으로부터 특징벡터를 추출하도록 하였고, 이를 FPGA로 코팅하여 시뮬레이션 하였다. 인식 모듈에서는 추출된 특징 벡터에 매하여 HMM 기반 인식 알고리즘을 적용하여 발성한 단어를 인식하도록 하였고, 이를 DSP에 코팅하여 시뮬레이션 하였다. 시뮬레이션 결과 실시간 립리딩 시스템이 하브웨어로 구현 가능함을 알 수 있었다.
Pae, Chi-Un,Wang, Sheng-Min,Han, Changsu,Lee, Soo-Jung,Patkar, Ashwin A,Masand, Praksh S,Serretti, Alessandro Journal of Psychiatry and Neuroscience] 2015 JOURNAL OF PSYCHIATRY AND NEUROSCIENCE Vol.40 No.3
<P>Vortioxetine was approved by the U.S. Food and Drug Administration (FDA) in September 2013 for treating major depressive disorder (MDD). Thus far, a number of randomized, double-blind, placebo-controlled clinical trials (RCTs) of vortioxetine have been conducted in patients with MDD. We performed a meta-analysis to increase the statistical power of these studies and enhance our current understanding of the role of vortioxetine in the treatment of MDD.</P>
Pae, Chi-Un,Chiesa, Alberto,Porcelli, Stefano,Han, Changsu,Patkar, Ashwin A.,Lee, Soo-Jung,Park, Moon Ho,Serretti, Alessandro,De Ronchi, Diana S. Karger AG 2011 Neuropsychobiology Vol.65 No.1
<P><I>Aim:</I> The present study aimed to explore whether some single nucleotide polymorphisms (SNPs) within the <I>BDNF</I> gene could be associated with major depression (MD), bipolar disorder (BD) and schizophrenia, and whether they could predict clinical outcomes in Korean inpatients treated with antidepressants, mood stabilizers and antipsychotics, respectively. <I>Methods:</I> One hundred and forty-five patients with MD, 132 patients with BD, 221 patients with schizophrenia and 170 psychiatrically healthy controls were genotyped for 5 <I>BDNF</I> SNPs (rs2030324, rs7103873, rs10835210, rs11030101 and rs6265). Baseline and final clinical measures - including the Montgomery-Asberg Depression Rating Scale, Young Mania Rating Scale and Positive and Negative Symptoms Scale for patients with MD, BD and schizophrenia, respectively - were recorded. <I>Results:</I> rs10835210 CA and rs11030101 AT genotype frequencies were higher in BD and schizophrenia patients than in healthy and MD subjects. No significant association was found with clinical improvement. <I>Discussion:</I> Our findings provide evidence of an association between BDNF and BD and schizophrenia. However, taking into account the several limitations of our study, including the moderately small sample size, further research is needed to draw more definitive conclusions.</P><P>Copyright © 2011 S. Karger AG, Basel</P>
Atypical antipsychotics as a possible treatment option for irritable bowel syndrome
Pae, Chi-Un,Lee, Soo-Jung,Han, Changsu,Patkar, Ashwin A,Masand, Prakash S Informa UK, Ltd. 2013 Expert opinion on investigational drugs Vol.22 No.5
<P><B><I>Introduction:</I></B> Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder (FGID) that is characterised by chronic abdominal pain, discomfort, bloating, and alteration of bowel habits. Although the pathophysiology of IBS is not fully understood, it is believed that psychiatric comorbidities are highly common in such patients. A variety of psychotropic medications are widely used in the treatment of IBS, particularly older antidepressants such as tricyclic antidepressants (TCAs).</P><P><B><I>Areas covered:</I></B> With the advent of newer antidepressant classes with better safety and tolerability compared with TCAs, such as serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), clinicians now have more advanced treatment options for treating IBS. Additionally, some atypical antipsychotics (AAs) have recently received approval for treatment of major depressive disorder (MDD). Some AAs may have potentials based on their pharmacodynamic profile and proven benefit for mood symptoms, pain, anxiety and sleep disturbances. This article describes the potential rationale, clinical data and practical aspects involved in the use of AAs for patients with IBS.</P><P><B><I>Expert opinion:</I></B> Atypical antipsychotics (AAs) may have a role in the treatment of irritable bowel syndrome (IBS) based on the currently available findings, although there is no clear evidence, and a number of clinical issues to be addressed in the use of AAs for the treatment of IBS.</P>
Association of sedative-hypnotic medications with suicidality.
Pae, Chi-Un,Koh, Jun Sung,Lee, Soo-Jung,Han, Changsu,Patkar, Ashwin A,Masand, Prakash S Future Drugs Ltd 2011 Expert review of neurotherapeutics Vol.11 No.3
<P>Evaluation of: Brower KJ, McCammon RJ, Wojnar M, Ilgen MA, Wojnar J, Valenstein M. Prescription sleeping pills, insomnia, and suicidality in the National Comorbidity Survey Replication. J. Clin. Psychiatry DOI: 10.4088/JCP.09m05484gry (2010) (Epub ahead of print). Several studies have investigated the association between sedative-hypnotics and suicidality, as such medications not only serve as a method for suicide, but are also involved in the usual options for treating psychiatric and medico-surgical disorders. According to population-based studies in Europe, Asia and the USA, sedative-hypnotic medications were significantly associated with suicide. However, these studies failed to address psychiatric comorbidities, new hypnotic medications, such as zolpidem, and the specific times at which such medications were used. Recently, Brower and colleagues have investigated the association of the prescription of sedative-hypnotic drugs with suicidality, to determine whether such medications were associated with suicidal ideation, suicide plans and suicide attempts in a large-cohort sample. They found that the use of sedative-hypnotic medications was significantly associated with suicidal ideation, suicide plans and suicide attempts. In addition, the use of sedative-hypnotic medications was a stronger predictor than insomnia of both suicidal ideation and suicide attempts. This article will discuss the relationship between prescription of sedative-hypnotic medications and suicide in the context of the potential limitations and significance of this recent research.</P>